Oruka Therapeutics, Inc.
ORKA
$66.93
$2.874.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.33% | 32.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.82% | 0.96% | |||
| Operating Income | -5.82% | -0.96% | |||
| Income Before Tax | -7.56% | 2.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.56% | 2.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.56% | 2.29% | |||
| EBIT | -5.82% | -0.96% | |||
| EBITDA | -5.78% | -0.93% | |||
| EPS Basic | -6.34% | 17.65% | |||
| Normalized Basic EPS | -6.09% | 20.87% | |||
| EPS Diluted | -6.34% | 17.65% | |||
| Normalized Diluted EPS | -6.09% | 20.87% | |||
| Average Basic Shares Outstanding | 1.38% | 23.49% | |||
| Average Diluted Shares Outstanding | 1.38% | 23.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||